FDA Licensed Ebola Virus Therapeutics

The Biomedical Advanced Research and Development Authority (BARDA), operating under the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, is conducting market research through a Sources Sought Notice to identify biopharmaceutical partners with FDA-licensed therapeutics for treating Ebola virus infections. Interested respondents who are sponsors of FDA-approved Ebola therapeutics must submit responses by March 13, 2026, at 3:00 PM US EDT through the BDR Portal. Submissions are limited to five pages and must address three primary areas: an overview of the therapeutic including product type, mechanism of action, and dosing regimen; comprehensive regulatory and licensure information including FDA approval date, approved indications, contraindications, and warnings; and manufacturing capability to produce cGMP-compliant product at 2,000-liter scale or higher. Respondents should refrain from including proprietary information in their submissions and must register for a BDR Portal account prior to submission. Points of contact for this opportunity are Yifan Yang and Justin Moore at BARDA.

This Sources Sought Notice carries no set-aside designation and is issued solely for information and planning purposes without obligating the government to award a contract or reimburse any submission costs. No incumbent contractors or specific award values are identified in this pre-solicitation notice. The market research initiative seeks to establish baseline information on existing FDA-licensed Ebola therapeutics and manufacturing capabilities in the biopharmaceutical sector. Respondents should note that BARDA is particularly interested in manufacturing scalability, with submissions required to address whether respondents currently possess or can develop cGMP manufacturing capacity at the 2,000-liter scale within a five-year timeframe. This notice falls under Product Service Code 6505 (Drugs and Biologicals) and represents BARDA's effort to assess potential future acquisition opportunities for medical countermeasures against emerging infectious disease threats.